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OBJECTIVES:Herpes zoster (HZ) and post-herpetic neuralgia (PHN) are painful con-
ditions that can have a substantial negative impact on patients’ lives. UK-specific
patient reported outcome (PRO) data on the debilitating impact of these conditions
is limited, however. A large-scale UK cross-sectional study, therefore, has recently
been conducted to address these limitations and further inform the scientific com-
munity. Findings from this study are summarised. METHODS: A combined total of
382 HZ and PHN patients over the age of 50 were recruited from 49 sites throughout
the UK. Participants were required to complete validated PRO measures of pain and
health-related quality of life (HRQoL), including the Zoster Brief Pain Inventory
(ZBPI) and the Medical Outcomes Study Short-Form 36 (SF-36). RESULTS: Pain was
a prominent symptom among patients, with more than 50% reporting experiencing
pain in the preceding 24 hours at levels typically considered to have a significant
impact on HRQoL (i.e. ZBPI worst pain 5). This was reflected in SF-36 domain and
summary scores that were significantly lower in HZ and PHN patients compared to
age-matched norms (p  0.05). When compared to normative samples, clinically
meaningful differences were observed among HZ and PHN samples across SF-36
domains assessing aspects of physical and mental well-being. In both groups,
HRQoL was inversely associated with levels of reported pain. CONCLUSIONS: Find-
ings indicate that the acute presentation of HZ and the development of PHN, the
most common complication of HZ and that can persist for several months, are
painful experiences that can have a significant impact on the physical and mental
wellbeing of HZ/PHN sufferers.
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OBJECTIVES: There is a growing debate regarding switching prescription (Rx) drugs
to over-the-counter (OTC) for chronic conditions as a viable option in the brand
lifecycle management and cost control. Further, patients are increasingly involved
in making informed treatment-related decisions. Using a novel patient registry, the
current study assessed satisfaction across ten widely used Rx and OTC medications
and evaluated the impact of Rx versus OTC status on treatment satisfaction for
these medications.METHODS:The registry recruited patients from multiple sourc-
es: physicians, pharmacies, and online referrals, to report ongoing medications on
www.MediGuard.org. A random sample of these patients was contacted to com-
plete the Treatment Satisfaction Questionnaire for Medication (TSQM) Version-I, a
14-item reliable and valid instrument to capture patients’ satisfaction with medi-
cation. The TSQM yields scores on four domains: effectiveness, side-effects, con-
venience, and global satisfaction. The study included patients on any of the ten Rx-
levothyroxine, metformin, atorvastatin, simvastatin, lisinopril, zolpidem, aripipra-
zole, esomeprazole, duloxetine, montelukast (n9,387) or OTC medications- ibu-
profen, acetaminophen, aspirin, multivitamin, cetrizine, omeprazole, omega,
naproxen, calcium carbonate, and loratadine (n7,226). Descriptive statistics and
regression analyses explored the differences in patients’ satisfaction across Rx
versus OTC medications. RESULTS: Overall, patients had mean (SD) age of 56.9
(12.4) years; 70.5% females and 73.8% White. The mean TSQM scores ranged from
61.4, 63.2 (acetaminophen, metformin) to 72.7, 76.4 (omeprazole, esomeprazole) on
effectiveness, from 93.0, 81.5 (cetirizine, aripiprazole) to 99.1, 97.6 (multivitamin,
esomeprazole) on side-effects, from 76.4, 78.1 (acetaminophen, metformin) to 88.2,
89.1 (loratadine, montelukast) on convenience and from 61.7, 61.1 (naproxen, met-
formin) to 73.8, 75.4 (cetirizine, esomeprazole) on global satisfaction. Compared to
Rx, OTC showed better side-effects profile and global satisfaction but had lower
effectiveness and convenience (p0.001) after adjusting for age, gender, race, self-
reported severity, and co-medications. CONCLUSIONS: The findings suggest that
differences in patients’ satisfaction profiles are associated with Rx versus OTC
medications.
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OBJECTIVES: We provided a comprehensive and detailed overview of the Spanish
burden of disease study for the year 2008. METHODS: We calculated disability-
adjusted life years (DALYs) at a country level using the methodology developed in
the Global Burden of Disease (GBD) study. DALYs were divided into years of life lost
because of premature mortality (YLLs) and years of life lived with disability (YLDs),
and are presented by sex and by age groups. Results were obtained using Spanish
specific-mortality data for the year 2008 and morbidity data estimated for Euro-A
region (European countries with very low mortality, including Spain) of the GBD
study. Data were analysed and prepared in GesMor and Epidat software. RESULTS:
In the year 2008, DALYs lost due to all diseases and injuries was estimated at 5.1
million (DALY rate per 1000 Spanish people of all ages and both sexes: 111.0). From
the total number of DALYs, 41.4% were due to premature mortality (YLLs) and
58.6% were due to disability (YLDs). Chronic non-communicable diseases ac-
counted for 89.2% of the total number of DALYs. The three main causes of DALYs
were neurological and mental disorders (29.9%), malignant neoplasms (15.8%), and
cardiovascular diseases (12.5%). The leading specific causes of DALYs were unipo-
lar depression (5.5%), ischaemic heart disease (5.5%), lung cancer (5.3%) and alcohol
abuse (4.7%) among males, and unipolar depression (11.7%), dementias (10.0%),
hearing loss (4.2%) and cerebrovascular disease (3.5%) among females.
CONCLUSIONS: Measuring DALYs specifically for Spain provides a systematic
analysis of health losses at a population level. The findings from this study suggest
that chronic non-communicable diseases would benefit from increased evidence-
based public health actions.
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OBJECTIVES:Calculate the country-level scores for the SF-36v2 subscales and com-
ponents for women with idiopathic menorrhagia treated with LNG-IUS; explore
between-country variability in HRQL experience of this condition; and evaluate the
treatment effect in different geographical settings. METHODS: Baseline and 12-
month data from a prospective, observational study of women with idiopathic
menorrhagia from 9 countries (Bulgaria, Croatia, India, Jordan, Romania, Russia,
Saudi Arabia, Serbia and Montenegro, and Turkey) were analyzed. Scores were
calculated for each of the eight domains and Physical and Mental component sum-
maries (PCS and MCS) of the SF-36v2. Hierarchical modeling was applied to account
for nested nature of observations within the countries. Frequentist mixed effects
regressions in STATA and Bayesian Markov Chain Monte Carlo simulation in Win-
BUGS were used to calculate country-level estimates, controlling for covariates.
RESULTS: Idiopathic menorrhagia negatively affects HRQL in different geographic
settings; in most countries baseline mean MCS scores are more than one standard
deviation (10 units) below the normative UK mean. Between-country variability
was confirmed in Bayesian and Frequentists analysis for baseline subscales (range:
36-86) and MCS and PCS (range: 35-51), indicating variation in experience with
menorrhagia. In general, 12-month estimates were much higher than those at
baseline, indicating substantial improvement in HRQL while on treatment, regard-
less of country. In addition, there was a consistent, positive relationship of haemo-
globin with the SF-36v2 subscales and the MCS. CONCLUSIONS:Women in 9 coun-
tries in the study are negatively affected by menorrhagia, though country-level
variation was seen. Improvement in HRQL while on treatment was consistent
across geographic settings. Exploration of potential country- or patient-level ef-
fects is recommended in future research.
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OBJECTIVES: Assess the impact of the treatment of urinary disorders of the lower
urinary tract related to benign prostatic hypertrophy (BPH) using medical treat-
ment under actual conditions of use. METHODS: A pragmatic cohort of patients
treated medically, was followed up for 6 months, using several validated question-
naires: IPSS, MSF4, and SF12. RESULTS:A total of 146 patients treated with Serenoa
Repens (hexanic extract) were evaluated, the mean age was 65.64 8.82 years, and
on average the diagnosis had been made 11 months previously. At 6 weeks, the IPSS
was significantly improved (p0.0001). This improvement in the IPSS score be-
tween 6 weeks (11.086.17) and inclusion (15.056.80) was 4 points. An improve-
ment was also observed at 3 months. At 6 months, the p-value was also significant
(p0.0001). The improvement in the IPSS score between 6 months (7.78423) and
inclusion (14.796.90) was 7 points.The physical dimension (50.187.39 at inclu-
sion) of the SF12 improved significantly (p0.0005) from the 6th week (52.466.10),
an improvement (2.51 points) that was confirmed at 6 months (52.076.54)
(p0.0052) in comparison with inclusion (49.567.53). The mental dimension
(49.187.63 at inclusion) of the SF12 improved significantly (p0.0069) at 6 month
(51.816.59). Improvement of 2.63 points. The MSF4 was unchanged.
CONCLUSIONS:We observed an improvement in the IPSS score from the 6th week;
this statistical improvement was confirmed by a significant clinical improvement
in the 6th month. This favourable progression is consistent with the improvement
observed for both dimensions of the SF12.
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OBJECTIVES: The aim of this study was to measure Health Related Quality of Life
among Pharmacy students at Medical University of Warsaw. METHODS: In March
2011, students from the Faculty of Pharmacy, Medical University of Warsaw were
surveyed with a set of HRQoL questionnaires. The survey was conducted in the
middle of the semester, when students have no exams, nor tests and was a part of
long-term Pharmacoeconomic Student Chapter’s project. Students self-completed
pen and pencil versions of questionnaires and didn’t receive any compensation.
They were asked to give information regarding sex, age, year of study, average
grade during the previous year of study and to complete final official Polish version
of EQ-5D-5L, followed by EQ-VAS, SF-36 v.1 and EQ-5D-3L. RESULTS: Three hun-
dred eighty three students were approached, 369 responded to EQ-5D-5L and SF-36
and were included in the final analysis. Missing data included: sex in 1 respondent,
age in 2 and EQ-VAS in 6 respondents. Concerning SF-36 dimensions, students
reported major problems in vitality 53.69  18.47 as opposed to physical function-
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